Cooley: Vaxcyte Announces $862.5 Million Public Offering
February 06, 2024
February 06, 2024
PALO ALTO, California, Feb. 6 -- Cooley, a law firm, issued the following news release:
Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering. Partners John McKenna and Mark Weeks led the Cooley team advising Vaxcyte.
Vaxcyte offered 12,695,312 shares of common stock priced at $64 per share, which includes the full exercise of the underwriters' option to purchase an additional 1,757,812 shares, along wi . . .
Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering. Partners John McKenna and Mark Weeks led the Cooley team advising Vaxcyte.
Vaxcyte offered 12,695,312 shares of common stock priced at $64 per share, which includes the full exercise of the underwriters' option to purchase an additional 1,757,812 shares, along wi . . .